Phase II study of cisplatin in recurrent astrocytomas in adults: a Southwest Oncology Group Study

Thirty-one evaluable adults with recurrent astrocytomas were treated with Cisplatin 35 mg/m2 I.V. daily for three days every 3-4 weeks. All patients had previously been irradiated and most had previously received chemotherapy. Approximately half had poor performance status. Two patients experienced complete remissions and two additional patients experienced partial remissions. Three patients stabilized. Gastrointestinal toxicity was generally mild. Further studies are planned of Cisplatin in combination with other agents.